FOR US HEALTHCARE PROFESSIONALS ONLY
For adults living with schizophrenia
Repeated relapses and cycles of failure on oral antipsychotics can shatter lives
Repeated relapses and cycles of failure on oral antipsychotics can shatter lives
SYMPTOM STABILITY
CAN’T WAIT
See how INVEGA SUSTENNA® can provide patients
with superior symptom control today
with superior symptom control today
Rapid disease progression occurs within the first 3-5 years post diagnosis1,2
Delayed symptom control can lead to a dangerous downward trend of repeated relapses, worsening symptoms, and increasing disability for adults with schizophrenia2,3
Achieving effective symptom control earlier after diagnosis is critical1,2,4
Effective, sustained symptom control is the foundation of a comprehensive treatment plan, with medication being 1 part of a multipronged approach.1,2
Earlier intervention with
INVEGA SUSTENNA® can help delay time to relapse5-8
INVEGA SUSTENNA® can help delay time to relapse5-8
It's never too late to offer patients the consistent medication delivery of
once-monthly
INVEGA SUSTENNA®.5
Did you know adults with schizophrenia are:
3x 
more likely to experience a negative housing change, such as becoming homeless, after 1 relapse9
3x
more likely to be incarcerated after experiencing 1 relapse9
66.2%
more likely to be unemployed with 1 relapse experience vs patients with no relapses9
A comprehensive treatment plan, which could include cognitive behavioral therapy and psychosocial services, can help patients address these challenges.
Help avoid cycles of relapse associated with daily orals. Prescribe INVEGA SUSTENNA®—the #1 prescribed long-acting injectable.10
In a 15-month study with
a real-world* design:
a real-world* design:
INVEGA SUSTENNA® was studied vs a group of 7 commonly prescribed oral antipsychotics5,6†
In a 24-month
international‡ study:
international‡ study:
INVEGA SUSTENNA® was studied vs a group of common oral antipsychotics in adults diagnosed with schizophrenia within 1 to 5 years7
In a post hoc analysis of
these 2 studies:
these 2 studies:
The risk of relapse with INVEGA SUSTENNA® in
adult patients was evaluated based on time since diagnosis (ranging from 0-5 years)8
adult patients was evaluated based on time since diagnosis (ranging from 0-5 years)8
INVEGA SUSTENNA® was evaluated in 4 short-term and 1 longer-term placebo-controlled trials5
See pivotal studies
*Real-world was defined by patient selection and clinically meaningful outcome measures.6
†The 7 oral antipsychotics included in the comparative arm accounted for 74% of oral schizophrenia treatment during the study period.11
‡The study was conducted in 26 countries, excluding the United States.7
References: 1. Birchwood M. Early intervention and sustaining the management of vulnerability. Aust N Z J Psychiatry. 2000;34 Suppl:S181-184. 2. Tandon R, Nasrallah H, Akbarian S, et al. The schizophrenia syndrome, circa 2024: what we know and how that informs its nature. Schizophr Res. 2024;264:1-28. 3. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches [published correction appears in Biol Psychiatry. 2002;51(4):346]. Biol Psychiatry. 2001;50(11):884-897. 4. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28(2):325-334. 5. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 6. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 7. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 8. Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: an integrated patient-level meta analysis of the PROSIPAL and PRIDE studies. Neuropsychiatr Dis Treat. 2024;20:2227-2235. 9. Lin D, Joshi K, Keenan A, et al. Associations between relapses and psychosocial outcomes in patients with schizophrenia in real-world settings in the United States. Front Psychiatry. 2021;12:695672. 10. Data on file. Janssen Pharmaceuticals, Inc. 11. Data on file. Janssen Pharmaceuticals, Inc.